11:34 AM EST - Zymeworks Inc. : Announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for a plenary session presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland from November 13-16. Zymeworks Inc.
shares T.ZYME are trading unchanged at $16.50.
